An experimental drug developed at Northwestern University has demonstrated further promise as an early intervention for ...

New research, published in Nature, has provided the first ever population-based data on the frequency of Alzheimer's disease ...

A newly revealed molecular tug-of-war may have implications for better understanding how a multitude of diseases and ...

Cardiac amyloidosis is becoming increasingly recognized as an etiology for heart failure (HF). Most cases of amyloid cardiomyopathy will fall into one of two categories: light-chain amyloid (AL) ...

The diagnosis of cardiac ATTR amyloidosis is frequently missed or delayed due to the transitional requirement that a tissue sample (biopsy) is required to confirm the diagnosis. A nuclear medicine ...

Cambridge, Massachusetts, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s ...

The trial, expected to enroll 128 patients, remains on track to report 6-month interim data in Q2 2026 and final 12-month top-line results in Q4 2026. Cambridge, Massachusetts, Sept. 03, 2025 (GLOBE ...

A team from the Microbiology Department at the Icahn School of Medicine at Mount Sinai has discovered three powerful monoclonal antibodies from a person who had previously been infected with mpox ...

Researchers at Baylor College of Medicine have developed an artificial intelligence (AI) model that reveals how protein modifications link genetic mutations to disease. The method, called DeepMVP and ...

CAMBRIDGE, Massachusetts , July 29, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to the discovery and development of therapeutic ...

MM often goes undetected until its later stages because it presents with non-specific symptoms, including fatigue, weight loss, bone pain, and recurrent infections. 2,3 However, better awareness, ...